Second Line Breast Cancer Trial

Study identifier:9238IL/0021

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-Blind, Randomized, Multi-center Trial comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long acting ICI 182,780) with 1mg Arimidex (Anastrazole) in Postmenopausal Women with Advanced Breast Cancer.

Medical condition

Advanced breast cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Fulvestrant, Anastrozole, Anastrozole, Fulvestrant

Sex

Female

Actual enrollment

588

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 May 1997
Primary Completion Date: -
Study Completion Date: 01 Sept 2004

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria